{"id":62112,"date":"2026-04-01T21:15:54","date_gmt":"2026-04-01T13:15:54","guid":{"rendered":"https:\/\/flcube.com\/?p=62112"},"modified":"2026-04-01T21:15:55","modified_gmt":"2026-04-01T13:15:55","slug":"biogen-secures-fda-approval-for-high-dose-spinraza-regimen-in-spinal-muscular-atrophy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62112","title":{"rendered":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy"},"content":{"rendered":"\n<p><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved a <strong>high-dose regimen<\/strong> of <strong>Spinraza (nusinersen)<\/strong> for the treatment of <strong>spinal muscular atrophy (SMA)<\/strong>, with commercial availability expected within the coming weeks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-details\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Spinraza (nusinersen) \u2013 high-dose regimen<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Spinal muscular atrophy (SMA)<\/td><\/tr><tr><td><strong>U.S. Launch Timeline<\/strong><\/td><td>Available in coming weeks<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>European Union, Switzerland, Japan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dosing-regimen-specifications\">Dosing Regimen Specifications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatment-naive-patients\">Treatment-Na\u00efve Patients<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Loading Phase<\/strong>: Two 50 mg doses administered 14 days apart (shortened from previous regimen)<\/li>\n\n\n\n<li><strong>Maintenance Phase<\/strong>: 28 mg every four months<\/li>\n\n\n\n<li><strong>Key Benefit<\/strong>: Reduced treatment burden during initial phase<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-patients-switching-from-lower-dose-regimen\">Patients Switching from Lower-Dose Regimen<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Loading Phase<\/strong>: Single high-dose administration<\/li>\n\n\n\n<li><strong>Maintenance Phase<\/strong>: Continue every-four-month schedule at 28 mg<\/li>\n\n\n\n<li><strong>Key Benefit<\/strong>: Seamless transition with improved efficacy profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-significance\">Clinical &amp; Commercial Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SMA Treatment Landscape<\/strong>: Spinraza remains a cornerstone therapy in SMA despite competition from gene therapies like Zolgensma and Evrysdi<\/li>\n\n\n\n<li><strong>Patient Experience<\/strong>: High-dose regimen addresses key unmet need for reduced treatment frequency and improved convenience<\/li>\n\n\n\n<li><strong>Market Positioning<\/strong>: Strengthens Biogen&#8217;s competitive position against newer oral and gene therapy alternatives<\/li>\n\n\n\n<li><strong>Global Harmonization<\/strong>: U.S. approval aligns with existing approvals in EU, Switzerland, and Japan<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact-for-biogen\">Strategic Impact for Biogen<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revenue-implications\">Revenue Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Existing Patient Base<\/strong>: Opportunity to convert current Spinraza patients to high-dose regimen<\/li>\n\n\n\n<li><strong>New Patient Acquisition<\/strong>: Enhanced value proposition for treatment-na\u00efve SMA patients<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Potential for premium pricing based on improved dosing convenience<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>vs. Zolgensma (Novartis)<\/strong>: Addresses single-dose gene therapy competition with improved chronic treatment option<\/li>\n\n\n\n<li><strong>vs. Evrysdi (Roche)<\/strong>: Competes with oral alternative through enhanced intrathecal delivery regimen<\/li>\n\n\n\n<li><strong>Market Share Defense<\/strong>: Critical for maintaining Biogen&#8217;s leadership in SMA therapeutics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-background-spinal-muscular-atrophy\">Disease Background \u2013 Spinal Muscular Atrophy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Leading genetic cause of infant mortality; affects approximately 1 in 11,000 births<\/li>\n\n\n\n<li><strong>Pathophysiology<\/strong>: Caused by mutations in SMN1 gene leading to motor neuron degeneration<\/li>\n\n\n\n<li><strong>Treatment Window<\/strong>: Early intervention critical for optimal outcomes<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Multiple therapeutic options including Spinraza (antisense oligonucleotide), Zolgensma (gene therapy), and Evrysdi (oral small molecule)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial launch, and competitive dynamics for Spinraza. Actual results may differ due to risks including market adoption, competitive pressures, and reimbursement challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62113,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,15,24],"class_list":["post-62112","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved a high-dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA), with commercial availability expected within the coming weeks.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62112\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved a high-dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA), with commercial availability expected within the coming weeks.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62112\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T13:15:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T13:15:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy\",\"datePublished\":\"2026-04-01T13:15:54+00:00\",\"dateModified\":\"2026-04-01T13:15:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0103.webp\",\"keywords\":[\"Biogen\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62112#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62112\",\"name\":\"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0103.webp\",\"datePublished\":\"2026-04-01T13:15:54+00:00\",\"dateModified\":\"2026-04-01T13:15:55+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved a high-dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA), with commercial availability expected within the coming weeks.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62112\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0103.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62112#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved a high-dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA), with commercial availability expected within the coming weeks.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62112","og_locale":"en_US","og_type":"article","og_title":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy","og_description":"Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved a high-dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA), with commercial availability expected within the coming weeks.","og_url":"https:\/\/flcube.com\/?p=62112","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T13:15:54+00:00","article_modified_time":"2026-04-01T13:15:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62112#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62112"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy","datePublished":"2026-04-01T13:15:54+00:00","dateModified":"2026-04-01T13:15:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62112"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62112#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp","keywords":["Biogen","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62112#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62112","url":"https:\/\/flcube.com\/?p=62112","name":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62112#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62112#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp","datePublished":"2026-04-01T13:15:54+00:00","dateModified":"2026-04-01T13:15:55+00:00","description":"Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved a high-dose regimen of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA), with commercial availability expected within the coming weeks.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62112#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62112"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62112#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp","width":1080,"height":608,"caption":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62112#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62112"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62112\/revisions"}],"predecessor-version":[{"id":62114,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62112\/revisions\/62114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62113"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}